Table 6.
Data | χ2 | df | p | GFI | NNFI | CFI | SRMR | RMSEA |
---|---|---|---|---|---|---|---|---|
Baseline to Week 2 | ||||||||
MF | 30.16 | 20 | .07 | .95 | .97 | .98 | .04 | .07 |
Baseline to Week 1 | ||||||||
NXP | 53.78 | 20 | <.05 | .95 | .92 | .94 | .05 | .09 |
Week 1 to Week 2 | ||||||||
NXP | 48.57 | 20 | <.05 | .95 | .88 | .91 | .06 | .09 |
Week 2 to Week 4 | ||||||||
MF | 41.89 | 20 | <.05 | .91 | .82 | .87 | .07 | .10 |
NXP | 50.46 | 20 | <.05 | .94 | .85 | .89 | .06 | .09 |
Week 4 to Week 6 | ||||||||
MF | 38.97 | 20 | <.05 | .91 | .81 | .87 | .07 | .10 |
NXP | 50.61 | 20 | <.05 | .94 | .83 | .88 | .07 | .09 |
Note. GFI = goodness-of-fit index; NNFI = nonnormed fit index; CFI = comparative fit index; SRMR = standardized root mean square residual; RMSEA = root mean square error of approximation; MF = message framing study (baseline to Week 2 n = 120; Week 2 to Week 4 n = 102; Week 4 to Week 6 n = 95); NXP = naltrexone + patch study (baseline to Week 1 n = 220; Week 1 to Week 2 n = 197; Week 2 to Week 4 n = 185; Week 4 to Week 6 n = 178). Model 3, unitary factor = craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia.